Skip to Main Content

Regulators in Finland threatened to fine Novartis (NVS) for violating laws governing the distribution of prescription medicines through pharmacies and state-owned hospitals.

The Finnish Medicine Agency took the drug maker to task for allowing the Aimovig migraine drug to be made available at a reduced price to patients through hospitals on an outpatient basis, instead of through pharmacies. Another violation involved an attempt to limit patients who would have been eligible for the medicine at a reduced price, although further details were not disclosed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!